Theme watch · accelerating
medtech stocks to watch — June 2026
As of 2026-06-14
Busted-growth genomics name: the May 4 print cut FY26 guide 12% and broke reimbursement (ARR ~$3,300, ~$200 light). Price has doubled off the $32…
Broken growth (new patient starts -10-20% seq) bouncing into ADA on RSI 82.3 parabolic off a busted base; litigation circling event-relief, not a…
TAVR disruptor at fresh 52w-high but on momentum not news, into a live $250M ATM seller, real binary ~2028 idiosyncratic, MATURING.
Synthetic-DNA tools maker re-rating as a 2nd-order AI-drug-discovery enabler (Complex Genes launch, $1B rev by FY2031, adj-EBITDA breakeven…
Defensive med-tech turnaround, MATURING character, no narrative velocity; recovery bounce toward a depressed PT cluster wrong archetype for size.
Spatial-biology re-rate but Atera revenue is a 2027 story, Q1 -3% YoY, -7.3% outside-reversal off the high stretched, post-catalyst, idiosyncratic.
AI point-of-care ultrasound narrative accelerating: Q1 2026 revenue +25% YoY ($26.5M), Butterfly Embedded chip-licensing +147%, first FDA-cleared…
"3-mo price move" is the stock's market price change, not an orbyd return.
How this ranking is built
Names are scored on cross-sectional 3-month price momentum across the US equity universe and ranked highest-first. Membership in the medtech stocks cluster is assigned by a frontier model, currently read as accelerating.
Genomics/diagnostics leg leads: GH FDA approval of Guardant360 CDx + RBC initiation $185, TXG acquires Proteintech, TWST Piper initiation $85; devices side SENS Welldoc/ADA data, AVR French regulatory clearance. Broadened to fold the genomics-tools names in.
Questions
- What are the top medtech stocks right now?
- As of 2026-06-14, the medtech stocks with the strongest 3-month price momentum on orbyd are WGS, BBNX, AVR, TWST. This is a momentum ranking of price moves already made, not a recommendation.
- Is the medtech stocks theme accelerating or slowing?
- orbyd's model reads this cluster as accelerating as of 2026-06-14. Genomics/diagnostics leg leads: GH FDA approval of Guardant360 CDx + RBC initiation $185, TXG acquires Proteintech, TWST Piper initiation $85; devices side SENS Welldoc/ADA data, AVR French regulatory clearance. Broadened to fold the genomics-tools names in.
- How does orbyd rank medtech stocks?
- Each name is scored on cross-sectional 3-month price momentum across the US universe by a frontier model, then linked to its dated research dossier where one exists. Methodology is open; this is research, not advice.
Related
As of 2026-06-14 · research, not advice.